Recommendations for Molecular Testing in Non-Small Cell Lung Cancer (NSCLC)
October 5th 2022A panel of lung cancer experts provides an overview of molecular testing in early-stage non-small cell lung cancer (NSCLC) and recommendations for biomarkers to test for and at what treatment stages to perform testing.
Read More
Revolutionizing Targeted Therapy With EGFR Exon 20 and the Early-Stage NSCLC Setting
January 7th 2022Josh Sabari, MD; Nicholas C. Rohs, MD; and Balazs Halmos, MD, discuss the updates with targeted therapy as it relates to the early-stage setting of non–small cell lung cancer as well as those who harbor EGFR exon 20 insertion mutations.
Read More